维普期刊资源整合服务平台（V6.5）

34篇 您的检索式：作者名="BENGALA C"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Dasatinib as a sin- gle agent in triple-negative breast cancer: results of an open-label phase 2 study显示文摘	Finn RS Bengala C Ibrahim N	2011	Clin Cancer Res2011，17，21：	1
2	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previ- ously treated with high-dose chemotherapy: a retrospective study显示文摘	Bengala C Zamagni C Pedrazzoli P	2006	Br J Cancer2006，94，7：	1
3	Sorafenib in patients with advanced biliary tract carcinoma:a phase Ⅱ trial显示文摘	Bengala C Bertolini F Malavasi N	2010	Br J Cancer2010，102，1：	1
4	Sorafenib in patients with advanced biliary tract carcinoma:a phase II trial显示文摘	Bengala C Bertolini F Malavasi N		0，，01：	1
5	Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱtrial显示文摘	Bengala C Bertolini F Malavasi N	2010	Br J Cancer2010，102，1：	1
6	Epidermal growth factor receptor gene copy number KRAS mutation and pathological response to preoperative cetuximab, 5FU and radiation therapy in locally advanced rectal cancer显示文摘	Bengala C Patelli S Bertolini F	2009	Ann Oncol2009，20，2：	1
7	Sorafenib in patients with advanced billiary tract carcinoma: a phase II trial 显示文摘	C Bengala F Bertolini N Malavasi et a1	2010	Br J Cancer2010，102，1：	1
8	Phase Ⅱ trial of dasatinib in triple-negative breast cancer:results of study CA180059显示文摘	Finn RS Bengala C Ibrahim N	2009	Cancer Res2009，69，2：	1
9	Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱ trial 显示文摘	Bengala C Bertolini F Malavasi N	2010	Br J Cancer2010，102，1：	1
10	Dasatinib as a single agent in triple-negative breast cancer: results of an open-la- bel phase 2 study显示文摘	Finn R S Bengala C Ibrahirn N	2011	Clin Cancer Res2011，17，21：	1
11	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study显示文摘	Bengala C Zamagni C Pedrazzoli P	2006	Br J Cancer2006，94，：	1
12	Neoadjuvant treat- ment with single-agent cetuximab followed by 5-Fu, cetux- imab, and pelvic radiotherapy:a phase II study in locally advanced rectal cancer 显示文摘	Bertolini F Chiara S Bengala C	2009	Int J Radiat Oncol Biol Phys2009，73，2：	1
13	Prognostic role of EGFR gene copy number and K-ras mutation in patients with locally ad-vanced rectal cancer treated with preoperative chemoradiotherapy显示文摘	Bengala C Bettelli S Bertolini F	2010	Br J Cancer2010，103，7：	1
14	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial显示文摘	BENGALA C BERTOLINI F MALAVASI N	2010	Br J Cancer2010，102，1：	1
15	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy:a retrospective study显示文摘	Bengala C Zamagni C	2006	Br J Cancer2006，94，7：	1
16	Sorafenib in patients with advanced biliary tract carcinoma:a phase Ⅱ trial显示文摘	Bengala C Bertolini F Malavasi N	2010	Br J Cancer2010，102，1：	1
17	Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer 显示文摘	BERTOL1NI F CHIARA S BENGALA C	2009	Int J Radiat Oncol Biol Phys2009，73，2：	1
18	Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study显示文摘	Finn RS Bengala C Ibrahim N	2011	Clin Cancer Res2011，17，21：	1
19	Epidermal growth factor receptor gene copy number,K-ras mutation and pathological response to preoperative cetuximab,5-FU and radiation therapy in locally advanced rectal cancer显示文摘	Bengala C Bettelli S Bertolini F	2009	Ann Oncol2009，20，3：	1
20	Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy 显示文摘	Bertolini F Bengala C Losi L	2007	Int J Radiat Oncol Bid Phys2007，68，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示